EVAX — Evaxion Biotech A/S Income Statement
0.000.00%
- $10.61m
- $15.90m
- $0.07m
Annual income statement for Evaxion Biotech A/S, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.073 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 10.9 | 16.6 | 25.8 | 25.3 | 22.3 |
Operating Profit | -10.9 | -16.6 | -25.8 | -25.3 | -22.2 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -12 | -16.6 | -24.7 | -23.9 | -22.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.2 | -15 | -24.5 | -23.2 | -22.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.2 | -15 | -24.5 | -23.2 | -22.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.2 | -15 | -24.5 | -23.2 | -22.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.83 | -7.93 | -12.6 | -9.78 | -8.09 |